Free tool
FAERS Monitor: Urso 250
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020675 or its brand name (Urso 250, Ursodiol). Reports on generic versions are filed under their own applications.
Reports
22,309
Serious
17,866
80% of reports
Hospitalization
10,186
Death reported
3,055
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,842
- pruritus1,326
- diarrhoea1,284
- fatigue1,129
- nausea1,091
- pyrexia1,016
- drug ineffective987
- pneumonia791
- death730
- vomiting714
- headache647
- dyspnoea609
- rash577
- abdominal pain565
- decreased appetite557
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 180 |
| 2006 | 110 |
| 2007 | 277 |
| 2008 | 418 |
| 2009 | 486 |
| 2010 | 641 |
| 2011 | 908 |
| 2012 | 810 |
| 2013 | 226 |
| 2014 | 280 |
| 2015 | 428 |
| 2016 | 585 |
| 2017 | 908 |
| 2018 | 1,402 |
| 2019 | 1,264 |
| 2020 | 1,328 |
| 2021 | 1,584 |
| 2022 | 2,209 |
| 2023 | 2,018 |
| 2024 | 2,081 |
| 2025 | 2,369 |
| 2026 | 1,757 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,850 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pruritusSignal | 1,326 | 3.3 | 3.1 | 2,108 |
| pyrexiaSignal | 1,016 | 2.8 | 2.6 | 1,166 |
| pneumoniaSignal | 791 | 2.3 | 2.2 | 592 |
| abdominal painSignal | 565 | 2.3 | 2.1 | 414 |
| decreased appetiteSignal | 557 | 2.3 | 2.1 | 395 |
| off label use | 1,842 | 2.0 | 1.9 | 937 |
| diarrhoea | 1,284 | 1.9 | 1.8 | 541 |
| vomiting | 714 | 1.4 | 1.3 | 95 |
| fatigue | 1,129 | 1.4 | 1.3 | 115 |
| nausea | 1,091 | 1.3 | 1.2 | 78 |
| rash | 577 | 1.2 | 1.2 | 29 |
| dyspnoea | 609 | 1.0 | 0.9 | 0 |
| headache | 647 | 1.0 | 0.9 | 0 |
| death | 730 | 0.8 | 0.7 | 38 |
| drug ineffective | 987 | 0.7 | 0.7 | 129 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.